Form 4: Nautilus Biotechnology Director Acquires 45,000 Stock Options
SEC Form 4 Filing
Melissa B. Epperly, a director at Nautilus Biotechnology, acquired 45,000 stock options on June 14, 2024, according to a Form 4 filing with the SEC.
Summary
- Melissa B. Epperly, a director of Nautilus Biotechnology, Inc. (NAUT), filed a Form 4 with the SEC on June 17, 2024.
- The filing reports a transaction that occurred on June 14, 2024, where Epperly acquired 45,000 stock options.
- These options have an exercise price of $2.56.
- The options vest monthly over a period of one year, contingent upon Epperly's continuous service as a 'Service Provider' as defined in the company's 2021 Equity Incentive Plan.
- The options expire on June 14, 2034.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing regarding stock option grants, which is neither particularly positive nor negative.
Industry Context
This is a standard SEC filing related to stock option grants, a common practice in publicly traded companies to incentivize and retain key personnel.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of stock option grant |
| 06/14/2034 | Expiration date of the stock options |
| 06/17/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.